Sulayyim Hadi Jaber Al, Ismail Rohani, Hamid Abdullah Al, Abdul Ghafar Noraini
Interdisciplinary Health Unit, School of Health Science, Universiti Sains Malaysia (Health Campus), Kubang Kerian 11800, Kelantan, Malaysia.
Saudi Ministry of Health, Najran Health Affairs, Infection Prevention and Control Department, Najran, Saudi Arabia.
J Pharm Policy Pract. 2023 Dec 16;17(1):2290671. doi: 10.1080/20523211.2023.2290671. eCollection 2024.
The occurrence of antibiotic resistance (AR) has become a critical issue during the Novel coronavirus disease 2019 (COVID-19) pandemic. This study explores the experiences of healthcare commissioners with AR during the COVID-19 pandemic, identifies challenges, and provides recommendations for combating AR during pandemics.
This qualitative study was multi-centered and used a phenomenological approach. Semi-structured interviews were conducted between December 2022 and January 2023 among 11 health commissioners using video calls.
Seven themes emerged from the data, including knowledge of AR and its consequences, the antibiotic prescription system, the future of AR and potential contributory factors, the impact of COVID-19 on AR and their relationship, the experience of AR during the COVID-19 pandemic in healthcare facilities, barriers that prevent the misuse of antibiotics during pandemics, and recommendations regarding antibiotic resistance during pandemics.
The findings of this study could be used to inform policy and practice for government healthcare workers (HCWs) and the public. Furthermore, this study identified the main challenges of AR during the pandemic, and the recommendations of health commissioners were provided accordingly. Such recommendations could be beneficial on a national and international scale to reduce the impact of future pandemics on AR.
COVID-19: Novel coronavirus disease 2019; AR: Antibiotic Resistance; IPC: Infection prevention and control; MDRO: multi-drug resistant organism; ASP: Antimicrobial Stewardship Program; HCW: Healthcare worker; KSA: Kingdom of Saudi Arabia; WHO: World Health Organization; MOH: Ministry of Health; MOEWA: Ministry of Environment, Water, and Agriculture; AMR: Antimicrobial Resistance; PHCC: Primary Healthcare Center.
抗生素耐药性（AR）的出现已成为2019年新型冠状病毒病（COVID-19）大流行期间的一个关键问题。本研究探讨了医疗保健专员在COVID-19大流行期间应对AR的经历，确定了挑战，并为在大流行期间对抗AR提供了建议。
本定性研究采用多中心现象学方法。2022年12月至2023年1月期间，通过视频通话对11名卫生专员进行了半结构化访谈。
数据中出现了七个主题，包括对抗生素耐药性及其后果的了解、抗生素处方系统、抗生素耐药性的未来及潜在促成因素、COVID-19对抗生素耐药性的影响及其关系、医疗保健机构在COVID-19大流行期间抗生素耐药性的情况、大流行期间防止抗生素滥用的障碍以及关于大流行期间抗生素耐药性的建议。
本研究结果可用于为政府医护人员（HCWs）和公众的政策及实践提供参考。此外，本研究确定了大流行期间抗生素耐药性的主要挑战，并相应地提供了卫生专员的建议。这些建议在国家和国际层面可能有助于减少未来大流行对抗生素耐药性的影响。
COVID-19：2019年新型冠状病毒病；AR：抗生素耐药性；IPC：感染预防与控制；MDRO：多重耐药菌；ASP：抗菌药物管理计划；HCW：医护人员；KSA：沙特阿拉伯王国；WHO：世界卫生组织；MOH：卫生部；MOEWA：环境、水和农业部；AMR：抗菌药物耐药性；PHCC：初级卫生保健中心
